Optogenetics is an innovative neural photostimulation technology, with significant contributions from Japanese researchers whose expertise is highly regarded worldwide. Close collaboration with Nagoya Institute of Technology and Kyoto University is advancing the development of high-sensitivity rhodopsins specialized for vision restoration. This technology overcomes the longstanding issue of insufficient light sensitivity in the field of vision restoration. Furthermore, through joint research with Keio University School of Medicine, applied research on the foundational technology is progressing toward the practical realization of the world’s first gene therapy for vision restoration. The goal is to offer new treatment options for patients suffering from blindness or severe visual impairments.
遺伝子治療による視覚再生の早期実用化を目指す株式会社レストアビジョン(本社:東京都港区、代表取締役:堅田侑作、以下「レストアビジョン」)は、当社のリードパイプラインである視覚再生遺伝子治療薬「RV-00...
<本資金調達の目的> このたび本エクステンションラウンドにて調達した資金は、主に当社のリードパイプラインであるRV-001のグローバル開発を推進する費用へ充当するとともに、セカンドパイプラインも含めた...
<本資金調達の目的> このたび調達した資金は、当社のリードパイプラインであるRV-001にかかる製剤開発、非臨床試験、臨床試験の費用等に充当し、RV-001を用いた国内第1/2相試験を2024年に開始し、RV-001の...
<資金調達の目的> このたび調達した資金は、慶應義塾大学とともに採択された国立研究開発法人日本医療研究開発機構(AMED)等の補助金計3億円とあわせて、6億円の資金をもって、当社のリードパイプライン...

Our mission is to safeguard the health of people worldwide. We are an Osaka University-spun-off healthcare startup in the healthcare/preventive medicine field, developing and providing the “Blood Vessel Beauty” scope—which observes capillary blood flow from the fingertip without blood sampling—along with the capillary image analysis software ‘CAS’ and the cloud-based evaluation system “CAS-Rating.” We research the relationship between capillary data and health/disease risks, aiming to implement new health indicators and preventive medical services in society.

① Research and development of brain stimulation therapy devices. ② Development and sales of medical and healthcare applications.

A startup developing a drug discovery platform capable of simultaneously measuring intracellular signals over time using proprietary technology, addressing multi-factor and multi-target drug discovery. Accelerating efficient and comprehensive new drug development through high-dimensional data and AI analysis.

Tellme's original business was operating hair salons. Over years of observing changes in their clientele, and as a service for customers who could no longer visit the salon due to illness or aging, the company developed a technology to assess the risk of glycation (a measure of aging) through hair analysis. This technology is currently being promoted as a diabetes screening technology. After being featured at the World Expo, it gained significant attention from overseas countries and institutions for its ability to assess risk without the need for blood sampling. In Japan, the technology is also seen as contributing to behavioral change among the segment of the population indifferent to their own health (kenko mukanshinsō) within local municipalities. Tellme is now pursuing the commercialization of this service as a means of optimizing social security costs.